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Abstract—Semantic interoperability is essential to facilitate 
efficient collaboration in heterogeneous multi-site healthcare 
environments. The deployment of a semantic interoperability 
solution has the potential to enable a wide range of informatics-
supported applications in clinical care and research both within a 
single healthcare organization and in a network of organizations. 
At the same time, building and deploying a semantic 
interoperability solution may require significant effort to carry 
out data transformation and to harmonize the semantics of the 
information in the different systems. Our approach to semantic 
interoperability leverages existing healthcare standards and 
ontologies, focusing first on specific clinical domains and key 
applications, and gradually expanding the solution when needed. 
An important objective of this work is to create a semantic link 
between clinical research and care environments to enable 
applications such as streamlining the execution of multi-centric 
clinical trials, including the identification of eligible patients for 
the trials. This paper presents an analysis of the suitability of 
several widely-used medical ontologies in the clinical domain: 
SNOMED-CT, LOINC, MedDRA, to capture the semantics of 
the clinical trial eligibility criteria, of the clinical trial data (e.g., 
Clinical Report Forms), and of the corresponding patient record 
data that would enable the automatic identification of eligible 
patients. Next to the coverage provided by the ontologies we 
evaluate and compare the sizes of the sets of relevant concepts 
and their relative frequency to estimate the cost of data 
transformation, of building the necessary semantic mappings, 
and of extending the solution to new domains. This analysis 
shows that our approach is both feasible and scalable. 
I. INTRODUCTION 
Semantic interoperability is essential to facilitate efficient 
cross-organization collaboration in healthcare by addressing 
some of the many sources of heterogeneity that currently 
hamper data and information sharing: (1) Many clinical 
research and care systems, often home-grown, (2) Structured, 
semi-structured and free-text documents, (3) Local languages 
in the patient record systems, English in research systems, (4) 
Many standards and terminologies, but with relatively low 
adoption. 
The deployment of a semantic interoperability solution has the 
potential to enable a wide range of informatics-supported 
applications in clinical care and research, both within a single 
healthcare organization and in a network of organizations, by 
enabling exchange of data and information with shared 
meaning. At the same time, building and deploying a semantic 
interoperability solution may require significant effort to carry 
out data transformation and to harmonize the semantics of the 
information in the different systems. 
We aim to implement semantic interoperability in a pragmatic 
way, relying on existing healthcare standards and ontologies, 
focusing first on specific clinical domains and key 
applications, and gradually expanding the solution when 
needed. The general approach to semantic interoperability is 
described in [1]. 
The work described in this paper is carried out in the 
EURECA1 project which aims to create a bridge between 
clinical research and clinical practice by building advanced, 
scalable and secure solutions which link existing systems such 
as Clinical Trial (CT) and Electronic Health Record (EHR) 
systems. Semantic interoperability among EHR and CT 
systems, consistent with widely-accepted standards and 
ontologies, lies at the heart of the project. 
An important application that we aim to support in the 
oncology domain is streamlining the execution of multi-
centric clinical trials, including the identification of eligible 
patients for the trials. To support the efficient execution of 
post-genomic multi-centric clinical trials in cancer, we aim to 
automatically assess based on the available patient data 
whether a patient is suitable for enrollment in any of the 
available clinical trials. The population eligible for a trial is 
described by a set of free-text eligibility criteria that are both 
syntactically and semantically complex. The evaluation of the 
eligibility of a patient for a trial requires the (machine-
processable) understanding of the semantics of the eligibility 
criteria in order to further evaluate if the patient data satisfies 
these criteria. 
In order to facilitate the linkage between clinical trials and 
patient data, we need to select ontologies which sufficiently 
capture the content of the eligibility criteria in clinical trials 
and patients data sets. An important task is to identify 
candidate subsets of ontologies (instead of the mapping of 
entire ontologies), which enables us to create scalable and 
feasible solutions. 
This paper presents an analysis of the suitability of several 
medical ontologies widely-adopted in clinical research: 
SNOMED-CT (Systematized Nomenclature of Medicine -
Clinical Terms2), LOINC (Logical Observation Identifiers 
Names and Codes3), MedDRA (Medical Dictionary for 
Regulatory Activities*), to capture the semantics of the clinical 
trial eligibility criteria, of the clinical trial data, and of the 
corresponding patient record data (that would be relevant for 
the automatic identification of eligible patients). We detect 
subsets of ontologies that characterize the semantics of the 
eligibility criteria of trials in various clinical domains in 
oncology and compare these sets. Next, we evaluate the 
occurrence frequency of the concepts in the selected oncology 
domains in order to provide meaningful priorities for the task 
of mapping these ontology concepts in the eligibility criteria to 
the patient data model. We further assess the effort required to 
scale our approach to new domains, measured in terms of 
additional semantic mappings that need to be developed. 
Finally, we assess the coverage provided to our domains of 
interest by the selected ontologies and evaluate the need to 
extend the sets of selected concepts to best suit our clinical 
domains. 
1
 Enabling information re-Use by linking clinical REsearch 
This work focuses on the definition of the core dataset 
(defined as in [1]) that sufficiently covers the semantics of our 
clinical domains of interest. The identification of the core 
dataset relies on: (1) an automatic identification of the 
concepts sets in the eligibility criteria of clinical trials in the 
domains of breast cancer, lung cancer, sarcoma and 
nephroblastoma, (2) on the identification of the sets of 
concepts of selected ontologies that appear in the available 
patient record datasets, and (3) an evaluation of both sets of 
ontology concepts by the clinical and knowledge experts and 
an assessment of coverage of the selected ontologies for the 
domains of interest. 
In [2] we carried out an analysis in identifying the semantics 
of clinical trial eligibility criteria with the same set of 
ontologies: SNOMED-CT, LOINC and MedDRA. We 
identified the subsets of the ontologies (since mapping entire 
ontologies is not feasible because of their respective size) that 
sufficiently capture the content of the eligibility criteria of 
trials in breast cancer and compared with trials in cancers 
other than breast and in the cardiovascular domain. We also 
evaluated whether our modular approach for the selection of 
the sets of concepts based on the clinical domains is scalable 
and feasible, and prioritized relevant concepts based on their 
frequency in the breast cancer subset and on their co-
occurrence in trials in the other clinical domains. Our findings 
indicate that relatively small subsets (in terms of number of 
concepts) of the ontologies are required to capture the 
semantics of the eligibility criteria, and that the reuse of 
concepts across trials is very significant. This conclusion is 
strengthened by the current work. In addition, the current work 
also analyzes patient-record datasets and provides an 
evaluation of the coverage of the ontologies for each clinical 
domain of interest. This evaluation was carried out by clinical 
and knowledge experts. 
II. EXTENDING THE SEMANTIC SOLUTION 
The first implementation of our semantic solution for the 
domain of breast cancer is described in [3] and in [4] we 
present the initial results towards developing mappings 
between the eligibility criteria and the patient data model 
based on the HL7-RIM standard and on the selected 
ontologies. 
In this paper we continue to further extend and assess our 
semantic approach in other clinical domains in oncology: lung 
cancer, sarcoma and nephroblastoma, and with new datasets in 
all four oncology domains of focus. We identify the subsets of 
the ontologies that sufficiently capture the content of the 
eligibility criteria of trials and of the relevant data collected in 
the patient records in the clinical domains of lung cancer, 
sarcoma and nephroblastoma and compare with our results in 
breast cancer updated with the new datasets. From the patient 
record datasets we extracted and analyzed the concepts that 
are relevant for the oncology patient management. We also 
identified relevant concepts that are currently not supported by 
our semantic solution in order to evaluate the extensibility of 
the solution and the needed effort. 
The analysis of the semantics of the datasets in the oncology 
domains of interest is based on three medical ontologies: 
SNOMED-CT, MedDRA, and LOINC. These ontologies are 
considered the best choices due to their wider adoption in both 
clinical research and care. The scalability of our solution is 
achieved by modularization i.e., we identify a core subset of 
SNOMED-CT that covers each clinical domain of interest and 
allows us to model the available datasets. We continue this 
process when we need to add new concepts related to new 
trials and data sources in an already captured clinical domain, 
and we define new modules for each new domain. 
III. DESCRIPTION OF THE EXPERIMENTS 
The experiments consist of the identification of the core 
dataset information in (a) clinical trial description, such as 
clinical trial eligibility criteria, and (b) care datasets provided 
by clinical sites (e.g., from the EHR system). 
A. The identification of the core dataset information in 
clinical trial description 
For the analysis of the semantics of the clinical trial eligibility 
criteria, we selected trials published on ClinicalTrial.gov and 
extracted the eligibility criteria of those trials from the 
following clinical domains: breast cancer, lung cancer, 
sarcoma and nephroblastoma. ClinicalTrials.gov is a service of 
the U.S. National Institute of Health and lists more than 
157,327 trials with locations in all 50 states and in 185 
countries5. TABLE 1 shows the number of trials in each of the 
four domains. 
TABLE 1 NUMBER OF TRIALS IN THE EVALUATION 
Clinical domain 
breast cancer 
4232 
Lung cancer 
1598 
Sarcoma 
421 
Nephroblastoma 
172 
In the following section, we investigate the semantic similarity 
among clinical trials in the selected clinical domains, and 
compare the sets of concepts for these domains and the 
selected ontologies. Our main focus is finding semantic 
overlap between breast cancer and the other domains as this 
enables us to reuse a part of our semantic solution (which 
initially focuses on breast cancer). For the analysis we extract 
the concepts that are found in the eligibility criteria and use an 
annotator from BioPortal to identify the ontology concepts 
present in those criteria. BioPortal is an open repository of 
biomedical ontologies that provides access via Web browsers 
and Web services to ontologies [5]. The BioPortal results 
include information such as identifiers, labels and the UMLS 
semantic type of the concepts. The semantic types can provide 
additional information about the semantics of the criteria and 
identify similarity between concepts. The following ontologies 
were added to the annotator: SNOMED-CT, MedDRA and 
LOINC. 
5
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B. The identification of the core dataset information in 
available datasets provided by clinical partners 
The clinical users involved in the EURECA project and 
contributing to this work are the University of Oxford 
(UOXF), Institute Jules Bordet (IJB), MAASTRO clinic, 
German Breast Group (GBG), and the University of Saarland 
(UdS). The datasets contain EHR data, Case Report Forms 
(CRF) used in trials such TOP Trial and SIOP 2001/GPOH, 
Neo-adjuvant (GeparQuattro), Adjuvant (GAIN) and 
metastatic (TBP) breast cancer trials, and cancer registry 
concepts (such as morphology and topography) that have been 
manually extracted. The diseases in which datasets are 
provided are: breast cancer, radiation oncology in breast 
cancer and lung cancer, sarcoma and nephroblastoma. In this 
context, for data transformation we needed to address many of 
the relevant types of heterogeneity (e.g. system, structure, 
language, terminology, domain, etc.). 
For instance for the MAASTRO clinic dataset we extracted 
and analyzed EHR data which was initially represented as a 
mix of structured fields and free-text in the Dutch language. 
The data processing steps included the identification and 
extraction of the relevant concepts, the identification of 
corresponding ontology concepts when available and an 
evaluation of the mappings with the clinical experts. 
The clinical domain of MAASTRO is radiation oncology, and 
we particularly chose this dataset for the evaluation because it 
contains a mixture of free-text and structured data. The data 
files are annotated with NCIt (National Cancer Institute 
Thesaurus) codes. The free-text includes oncological history, 
medication and medical history. The NCIt annotation contains 
information such as the name of the disease, the date of 
diagnosis and the TNM stage [61. 
IV. EVALUATION RESULTS 
In this section we present (1) an analysis of the semantics of 
the clinical trial eligibility criteria based on relevant medical 
ontologies: SNOMED-CT, MedDRA and LOINC, (2) 
evaluate the sets of concepts that appear in a patient dataset 
provided by a clinical partner, and (3) an evaluation of the 
results by clinical partners. 
A. The identification of the core dataset information in 
clinical trial description 
TABLE 2 compares the sets of concepts for the four clinical 
domains and the three ontologies selected. We denote L as the 
set of lung cancer concepts, B as the set of breast cancer 
concepts and SN as the union of the sarcoma and 
nephroblastoma concepts (since the sets for these domains are 
relatively small compared to the lung cancer and breast cancer 
corpuses). The tables show that the lung cancer and breast 
cancer corpuses have significant subsets that are specific for 
those diseases, but also a large overlap. This implies that a 
large amount of concepts currently used in our semantic layer 
for breast cancer will be also relevant for lung cancer. We can 
also observe that for LOINC the largest set is the one that is 
the overlap among the four domains. For SNOMED-CT we 
observe that this is the second largest set. 
TABLE 2 SETS OF CONCEPTS FOR LUNG CANCER (L), SARCOMA 
AND NEPHROBLASTOMA (SN) AND BREAST CANCER (B) 
Subset 
L - (B U SN) 
L O B 
L O SN 
L n B n SN 
SN - (B U L) 
B O SN 
B - (SN U L) 
SNOMED-CT 
1666 
1976 
34 
2225 
506 
76 
3392 
MedDRA 
527 
499 
13 
399 
164 
18 
840 
LOINC 
427 
579 
61 
1006 
120 
33 
727 
FIGURE 1, FIGURE 2 and FIGURE 3 show for the three 
corpuses of trials the distribution of concepts across trials (for 
SNOMED-CT). We only show the top most frequent concepts 
and each concept is counted once per trial. The figures show 
that a large ratio of criteria is similar, but that new trials may 
introduce new concepts. A relatively small group of concepts 
occur in a large number of trials and there are concepts that 
occur less frequent for specific trials. We also see this 
phenomenon in the results presented in [2]. 
FIGURE 1 the number of lung cancer (y-axis) trials that include the top 
500 most frequently occurring SNOMED-CT concepts (x-axis). Concepts 
were counted once per trial. 
FIGURE 2 the number of sarcoma (y-axis) trials that include the top 500 
most frequently occurring SNOMED-CT concepts (x-axis). Concepts 
were counted once per trial. 
FIGURE 3 the number of nephroblastoma (y-axis) trials that include the 
top 500 most frequently occurring SNOMED-CT concepts (x-axis). 
Concepts were counted once per trial. 
TABLE 3 shows the averages of the number of ontology 
concepts per trial in the domains lung cancer, sarcoma and 
nephroblastoma, for the three selected ontologies. 
TABLE 3 THE AVERAGE NUMBER OF TRIALS PER ONTOLOGY 
lung cancer 
sarcoma 
nephroblastoma 
SNOMED-CT 
192 
245 
206 
MedDRA 
25 
31 
25 
LOINC 
112 
140 
115 
B. The identification of the core dataset information in a 
breast cancer dataset provided by a clinical site 
In this section we evaluate the concepts extracted from the 
MAASTRO breast cancer dataset. The groups of files are 
NCIt encoded, and free-text oncological history, medical 
history and medication. For each group, we extract the 
concepts that are found in the data and use the Bioportal 
annotator to identify the ontology concepts. 
1) NCI Thesaurus 
Every patient record in the MAASTRO dataset has at least one 
NCIt encoded element. An element has attributes such as an 
id, a code, and a preferred name. TABLE 4 shows a list of the 
diseases (with associated NCIt codes) and the coverage of the 
ontologies, for the breast cancer dataset. We used mappings 
that were created by the LOOM algorithm of NCBO6 and a 
clinical expert at MAASTO to validate and to complement the 
mappings. 
6http://bioontology.stanford.edu/wiki/index.php?title=BioPorta 
l_Mappings&redirect=no 
TABLE 4 COVERAGE BY MEDICAL ONTOLOGIES OF CONCEPTS 
IN MAASTRO BREAST CANCER DATASET (NO COVERAGES, 
100% COVERAGE=1.0) 
Breast cancer dataset (NCIt 
code) 
Breast Neoplasm (C2910) 
Invasive Ductal Carcinoma, Not 
Otherwise Specified (C4194) 
Invasive Lobular Breast 
Carcinoma (C7950) 
Ductal Breast Carcinoma In Situ 
(C2924) 
Malignant Breast 
Neoplasm(C9335) 
Medullary Breast Carcinoma 
(C9119) 
Mixed Lobular and Ductal 
Breast Carcinoma (C5160) 
Tubular Breast Carcinoma 
(C9135) 
Adenoid Cystic Breast 
Carcinoma (C5130) 
Malignant Breast Phyllodes 
Tumor(C4504) 
Coverage 
Mapped To 
SNOME 
D-CT 
X 
X 
X 
X 
X 
X 
X 
0.70 
MedDRA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
0.90 
LOINC 
X 
X 
0.20 
2) Oncological history 
The free-text oncological history contains TNM cancer staging 
codes and the dates associated with them. The TNM staging 
system is one of the most widely used cancer staging systems. 
The TNM system is based on the size and/or extent (reach) of 
the primary tumor (T), the amount of spread to nearby lymph 
nodes (N), and the presence of metastasis (M) or secondary 
tumors formed by the spread of cancer cells to other parts of 
the body [6]. We use regular expressions to extract the TNM 
stages and incorporate a pattern such that we can also extract 
the date of occurrence, e.g., the Dutch free-text "...9 
November 2012 pTINOMO mammacarcinoom..." contains 
"(pTINOMO, 2012)". TABLE 5 shows a list of the most 
frequent TNM cancer staging codes that were extracted. 
TABLE 5 MOST FREQUENT OCCURING TNM PARAMETERS 
WITH CORRESPONDING DEFINITION 
Category 
cTis 
cTl / 
pTl 
cT2 
NO 
Nl 
M0 
Definition7 
Carcinoma in situ 
Tumor 2 cm or less in greatest dimension 
Tumor more than 2 cm but not more than 5 
cm in greatest dimension 
No regional lymph node metastasis 
Spread to movable ipsilateral axillary lymph 
node(s) 
No distant metastasis 
Identified 
bV 
SNOMED-
CT 
SNOMED-
CT 
SNOMED-
CT 
SNOMED-
CT 
SNOMED-
CT 
SNOMED-
CT 
3) Medical history 
FIGURE 4 shows the number of occurrences of the top 10 
most frequent annotated concepts extracted from the medical 
history section of the breast cancer dataset. The figure shows 
that 'Hypertensive disorder', which can be caused by several 
breast cancer treatments, and 'Hysterectomy', which can 
lower the risk of certain cancers, are frequently occurring 
concepts within the dataset. In some cases we noticed that 
concepts with the same label (but with different identifiers) 
can also appear in different branches in the SNOMED-CT 
hierarchy (i.e., a term can have multiple interpretations). We 
needed clinical experts and the UMLS semantic types for 
further disambiguation. 
FIGURE 4 the number (y-axis) of occurrences of the top 10 most 
annotated concepts extracted from the medical history section (x-axis) in 
SNOMED-CT. 
• ll I III 
4) Medication 
FIGURE 5 shows the number of occurrences of the top 10 
most frequent annotated concepts extracted from the 
medication section of the breast cancer dataset. The figure 
shows that 'Tamoxifen' (a drug that is used to treat hormone 
receptor-positive breast cancer) is the most frequently 
occurring concept found in the breast cancer dataset. The 
annotator identified this concept as a 
'Pharmaceutical/Biological product' and as a 'Substance'. 
7
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FIGURE 5 the number (y-axis) of occurrences of the top 10 most 
annotated concepts extracted from the medication section (x-axis) in 
SNOMED-CT. The concepts 'Tamoxifen', 'Acetaminophen', 
'Simvastatin' and 'Metoprolol' are identified as a product and as a 
substance in the SNOMED-CT hierarchy. 
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5) Semantic types 
TABLE 6 shows the semantic types of the NCIt encoded 
section of the breast cancer dataset. The table shows that the 
semantic type 'Neoplastic Process', which in turn is a 'Disease 
or Syndrome' in the UMLS, is the most frequent occurring 
type. We can also see the same findings regarding the free-text 
medication (TABLE 7). Almost 90% of the data in that section 
is identified as a 'Pharmacologic Substance'. In the medical 
history section (TABLE 8) we see that 66% is identified as a 
'Disease or Syndrome'. 
TABLE 6 RATIO OF THE SEMANTIC TYPES FOR NCIt ENCODED 
SECTION OF THE BREAST CANCER DATASET (RELATIVE TO 
TOTAL NUMBER OF CONCEPTS) 
Semantic type 
Neoplastic Process 
Body Part, Organ, or Organ Component 
Qualitative Concept 
Spatial Concept 
Disease or Syndrome 
Finding 
Ratio 
0.559 
0.223 
0.204 
0.011 
0.010 
0.001 
TABLE 7 RATIO OF THE MOST FREQUENT SEMANTIC TYPES 
FOR THE MEDICATION SECTION OF THE BREAST CANCER 
DATASET (RELATIVE TO TOTAL NUMBER OF CONCEPTS) 
Semantic type 
Pharmacologic Substance 
Organic Chemical 
Disease or Syndrome 
Laboratory Procedure 
Steroid 
Element, Ion, or Isotope 
Biologically Active Substance 
Hormone 
Amino Acid, Peptide, or Protein 
Vitamin 
Ratio 
0.873 
0.794 
0.037 
0.034 
0.033 
0.028 
0.024 
0.022 
0.020 
0.014 
Semantic type 
Disease or Syndrome 
Therapeutic or Preventive Procedure 
Finding 
Pathologic Function 
Body Part, Organ, or Organ Component 
Congenital Abnormality 
Anatomical Abnormality 
Qualitative Concept 
Clinical Attribute 
Acquired Abnormality 
Ratio 
0.663 
0.235 
0.055 
0.039 
0.027 
0.026 
0.025 
0.011 
0.006 
0.004 
C. The coverage evaluation carried out by clinical experts 
TABLE 9 shows the coverage of the selected ontologies for 
each of the dataset introduced in Section III.B. The table 
indicates that SNOMED-CT has the highest coverage rate. 
Further analysis, however, revealed that SNOMED-CT is 
insufficient to cover more specific concepts such as 
radiotherapy concepts and gene related concepts (e.g., HER2). 
TABLE 9 COVERAGE OF DIFFERENT TERMINOLOGIES (NO 
COVERAGES, 100% COVERAGE=1.0) 
Dataset 
UOXF 
IJB 
MAASTRO 
GBG 
UdS 
BC dataset 
Sarcoma 
dataset 
CRF data 
TOP Trial 
Cancer 
Registry 
Morpholog 
y 
Cancer 
Registry 
Topograph 
y 
EHR 
TBP 
GAIN 
GeparQuatt 
ro 
SIOP 
SNOMED-
CT 
0.75 
0.74 
0.91 
0.98 
0.05 
0.70 
0.99 
0.95 
0.95 
0.96 
MedDRA 
0.33 
0.55 
0.43 
0.35 
0.01 
0.90 
0.70 
0.62 
0.61 
0 
LOINC 
0.37 
0.37 
0.66 
0.01 
0.007 
0.20 
0.29 
0.22 
0.21 
0.04 
V. RELATED WORK 
TABLE 8 RATIO OF THE MOST FREQUENT SEMANTIC TYPES 
FOR THE MEDICAL HISTORY SECTION OF THE BREAST 
In this paper we present an analysis of the semantics of the 
eligibility criteria and datasets of oncology trials and of the 
relevant patient record data based on widely-adopted medical 
ontologies: SNOMED-CT, MedDRA and LOINC. 
SNOMED-CT is a clinical vocabulary focused on accurately 
recording health care encounters and the associated electronic 
health information exchange. Although SNOMED-CT is 
sometimes criticized, it has a significant uptake in clinical 
practice, such as its use in HL7 messaging. MedDRA focuses 
on the regulatory process of drug development and is a 
medical vocabulary that is used by regulatory bodies and the 
regulated biopharmaceutical industry for data entry, retrieval, 
evaluation and display. MedDRA is used in clinical trials for 
reporting adverse events. LOINC has the purpose to facilitate 
the exchange and pooling of results for clinical care, outcomes 
management, and research. LOINC provides universal 
identifiers for laboratory and other clinical observations and it 
is a preferred code set for HL7 for laboratory test names in 
transactions between health care facilities, laboratories, 
laboratory testing devices, and public health authorities. 
In our previous work in the INTEGRATE8 project we 
analyzed the semantics of the eligibility criteria of clinical 
trials in the INTEGRATE domain of interest which is breast 
cancer. We defined the core dataset at the center of the 
semantic solution, linking trial descriptions to patient data as: 
"Soundly defined and agreed-upon clinical structures 
consisting of stand-based concepts, their relationships, 
quantification etc., that together sufficiently describe the 
clinical domain" [1]. In this paper we leverage the work in the 
INTEGRATE project and extend our semantic approach to 
other clinical domains such as lung cancer, sarcoma and 
nephroblastoma. 
In [7] the authors present a method that uses the Web 
Ontology Language (OWL) and the Semantic Web Rule 
Language (SWRL) for automatic recruitment of a patient to 
available clinical trials. The aim of their work is to show how 
it is possible to represent eligibility criteria of clinical trials 
using SWRL on top of a large domain specific ontology: NCI 
thesaurus. Their evaluations results indicate that this ontology 
provides the best coverage of the terms that appear in the 
patient datasets and in the selected eligibility criteria used in 
the set-up. Patient datasets and eligibility criteria, in the 
domain of prostate cancer, are represented with the Web 
Ontology Language and SWRL. The SWRL rules are queried 
over the observations containing patients' data to verify which 
inclusion and/or exclusion criteria are met. Then, the rules are 
computed and executed with the Jess rule engine. The end 
result is a list of inclusion and exclusion criteria with their 
associated observations. The authors conclude that a large 
majority of the criteria of selected trials can be represented but 
that a lack of corresponding concepts in NCIt is the main 
cause of failure. 
In [8] the authors present a modeling strategy of eligibility 
criteria in OWL that leverages open world assumption to 
address the missing information problem. The proposed OWL 
design pattern deals with scenarios in which inclusion criteria 
cannot be proven and exclusion criteria cannot be proven to be 
false. The analysis of a clinical trial shows that ignoring 
missing information (i.e., eligibility criteria which cannot be 
assessed) leads to too many rejections. Their strategy 
identified 30 patients, which were initially rejected, as 
potentially eligible for a clinical trial. 
In [9] the authors present a feasibility study for an ontology-
based approach to match patient records to clinical trials. The 
process involves formulating trials as queries and using the 
SHER reasoner to match the queries against a knowledge base 
8
 Driving excellence in Integrative Cancer Research through 
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integrate.eu/ 
to retrieve eligible patients. The authors present results in 
which challenges such as identifying and eliminating noise in 
patient data, and dealing with incomplete patient information 
are solved using their approach, for a real world patient dataset 
that is used in the analysis. 
VI. DISCUSSION AND CONCLUSIONS 
In our previous work we proposed a flexible and scalable 
approach to semantic interoperability and provided a first 
implementation. Our approach relies on the selection of 
suitable and widely-adopted ontologies that can provide 
sufficient coverage for the clinical domains and applications 
of interest. These ontologies are used to define the core 
dataset, i.e., subsets/modules that are used in our solution to 
provide semantic links among datasets in various relevant 
systems. 
For this modular approach to be feasible and scalable, (1) the 
modules capturing the semantics of each domain need to be 
relatively small to limit the effort required for data 
transformation and for the development of mappings, (2) the 
extensions to new domains or applications need to be 
manageable in terms of the numbers of concepts that need to 
be added, and (3) the selected ontologies need to provide good 
coverage (i.e., capture the semantics) for the relevant domains 
and applications. 
In [2] we have evaluated the feasibility of this approach for 
breast cancer in the context of supporting clinical trials. In 
this paper we assess the feasibility and scalability of this 
solution by extending it to new clinical domains and 
evaluating additional datasets from clinical care and research. 
We focus on the definition and analysis of the core dataset 
(i.e., modular subsets of existing ontologies) that sufficiently 
cover the semantics of the clinical domains of interest. The 
identification of the core dataset relies on: (1) an automatic 
evaluation of the concepts sets in the eligibility criteria of 
clinical trials in the domains of breast cancer, lung cancer, 
sarcoma and nephroblastoma, and (2) on the evaluation of the 
sets of concepts of selected ontologies that appeared in patient 
datasets (both from research and care) provided by clinical 
sites. 
Our results indicate that a relatively small set of concepts 
occurred in a large number of clinical trials and that there were 
concepts that occurred less frequently (only in specific trials). 
With these findings we can prioritize the implementation of 
semantic mappings starting with the most frequent concepts. 
Also, our results show that the effort of adding new trials is 
low since the additional sets of concepts that need to be 
mapped to relevant data are small. 
It can also be observed that the semantic overlap between the 
lung cancer and breast cancer domains is large. This implies 
that we can reuse a large part of our semantic mappings 
developed for breast cancer when extending the solution to the 
lung cancer domain. It also shows that this approach can be 
further generalized to new clinical and application domains, 
and that the cost of extending the implementation is relatively 
low. 
The evaluation of the different datasets by the clinical experts 
indicated that SNOMED-CT provides the best coverage for 
our data. However, further analysis revealed that SNOMED-
CT is insufficient to cover more specific concepts related for 
instance to radiotherapy or genomic data. For these domains 
other ontologies need to be evaluated. 
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